Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-human CD70 T-cell injection
- Development stage
- Phase 1
- Lead developer
- Shanghai HRAIN Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anti-human CD70 T-cell injection, also known by the code name HRAIN0701, is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by Hrain Biotechnology. This cell-based immunotherapy is designed to treat advanced or metastatic renal cell carcinoma (RCC) by targeting CD70 (cluster of differentiation 70), a member of the tumor necrosis factor ligand superfamily that is highly expressed on the surface of RCC cells but has limited expression in normal tissues. The treatment process involves collecting a patient's T cells, genetically engineering them ex vivo to express a CAR specific for CD70, and then re-infusing them into the patient to induce a targeted anti-tumor immune response. The therapy is currently undergoing Phase 1 clinical trials to evaluate its safety, tolerability, pharmacokinetics, and preliminary therapeutic activity in patients with advanced renal malignancies.
- Other names
- anti-human CD70 T-cell injectionAnti-Human CD70 CAR-T Cells
02
Targets
CD70 (Cluster of Differentiation 70)
Beyond the preview
Go deeper on anti-human CD70 T-cell injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-human CD70 T-cell injection.